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INTRODUCTION
The systemic lupus erythematosus (SLE) and myasthenia
gravis (MG) show certain similarities, in that they occur main-
ly in young women, are manifested by cycles of improvement
and exacerbation, and share positivity for antinuclear antibod-
ies (ANA) and thymus hyperplasia. The co-existence of SLE
and MG is well documented (1, 2). Thymectomy is a com-
mon therapeutic option in the treatment of MG, and systemic
autoimmune disorders have been detected in MG patients
several years after thymectomy. The development of SLE in
MG patients after thymectomy has been reported infrequent-
ly, and to our knowledge has not been reported previously in




A 36-yr-old woman developed fatigue and polyarthralgia
that involved the wrists, proximal interphalangeal (PIP) joints,
left knee, and left ankle, over a period of 2 months. She had
stiffness of joints in the morning lasting 3 hr. Eight months
previously, she had been diagnosed with MG based on the
typical history of diplopia, right eye ptosis, generalized mus-
cle weakness, positive response to edrophonium, and increased
decremental response after repetitive nerve stimulation. Five
months later, a thymectomy was performed to remove her
hyperplastic thymus, as her symptoms were not adequately
controlled with pyridostigmine. Pathological examination of
the thymus revealed focal lymphoid hyperplasia.
Examination of the patient showed the evidence of polyarthri-
tis of the wrists, right 3rd, 5th PIPs, left 2nd, 3rd PIPs, left
knee, and left ankle. There was no malar rash, photosensitiv-
ity, oral ulcer, hair loss, or Raynaud’ s phenomenon. Laboratory
data revealed an ESR of 45 mm/hr, anemia of 9.9 g/dL hemo-
globin, leukopenia of 1,600/ L, thrombocytopenia of 91,000/
L, and elevated LDH. The patient had a positive ANA of
1:1,280 (homogeneous), positive anti-dsDNA level of 57.3
IU/mL (normal <7), and decreased complement (C3, C4, CH50)
levels. The tests for cryoglobulin, lupus anticoagulant, and
anticardiolipin IgG and IgM antibodies were negative. The
remaining biochemical tests, coagulation profile, and urinal-
ysis were normal. This patient displayed four of the revised
criteria for SLE classification (9), i.e., polyarthritis, hemato-
logical findings, positive ANA, and anti-dsDNA antibodies.
She was treated with prednisolone (1 mg/kg) and hydroxy-
chloroquine, with gradual tapering off of the treatment, and
remained stable during the 3 yr of follow-up.
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Appearance of Systemic Lupus Erythematosus in Patients with
Myasthenia Gravis following Thymectomy
: Two Case Reports
We report two cases of systemic lupus erythematosus (SLE) in myasthenia gravis
(MG) patients who had undergone thymectomy. SLE developed in the patients 3
months or 13 yr after thymectomy, and polyarthritis was the main clinical manifes-
tation of SLE. Both patients fulfilled at least four of the revised criteria for the clas-
sification of SLE. In this report, we describe two postthymectomy lupus patients and
perform a comparative review of previous cases.
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Case 2
A 34-yr-old woman presented with aggravated polyarthral-
gia of the shoulders, PIPs, and knees, which had persisted for
2 yr. She had morning stiffness of both hand joints lasting 2
hr. Thirteen years previously, the patient had been diagnosed
as suffering from MG, and underwent thymectomy of a hyper-
plastic thymus.
Examination revealed that the patient had polyarthritis of
the PIPs, and a malar rash and photosensitivity that had start-
ed 1 yr earlier. There was no oral ulcer, hair loss, or Raynaud’ s
phenomenon. Laboratory data revealed an ESR of 13 mm/hr,
a positive ANA test of 1:640 (homogeneous), a positive anti-
dsDNA antibody level of 11.1 IU/mL (normal <7), and de-
creased levels of complements (C3, C4, and CH50). The results
of the CBC, urinalysis, and chemical analyses were normal.
The patient had five of the revised criteria for SLE (9): poly-
arthritis, malar rash, photosensitivity, positive ANA, and anti-
dsDNA antibodies. A non-steroidal anti-inflammatory drug
and hydroxychloroquine were administered to the patient, and
her symptoms improved. During the 2-yr follow-up period, the
patient was stable and did not suffer from any specific symp-
toms of SLE.
DISCUSSION
Surgical removal of the thymus gland is used successfully
to manage MG, which is an autoimmune disease in which
antibodies against the acetylcholine receptor inhibit neuromus-
cular transmission (10, 11). Although the precise mechanism
by which thymectomy produces a benefit to MG patients is
still unclear, this therapeutic option is indicated in all patients
with generalized MG between the age of puberty and at least
55 yr. However, in recent years, evidence has emerged of sys-
temic autoimmune disorders including SLE, Hashimoto’ s
thyroiditis, cutaneous vasculitis, and antiphospholipid syn-
drome occurring many years after thymectomy in patients
with MG or other immunological diseases (12).
The evidence that thymectomy induces autoimmune dis-
ease is based primarily on animal studies. New Zealand black
×New Zealand white F1-crossed (NZB×NZW F1) mice spon-
taneously develop a lupus-like disease with increasing age,
which is associated with uninhibited activation of polyclonal
B cells (13). When neonatal NZB×NZW F1mice were sub-
jected to thymectomy, there was a marked acceleration of dis-
ease, possibly due to the elimination of the thymic T-suppres-
sor cell population. Furthermore, reconstitution of these mice
with young syngeneic thymic grafts retarded the development
of autoimmunity (14). Studies have also been performed on
normal mice, in which the features of autoimmunity were
induced by the administration of polyclonal B cell activators.
The effects of neonatal thymectomy and long-term admin-
istration of polyclonal B cell activators were synergistic in pro-
voking anti-DNA antibody production, which suggests that
the intact thymus protects against the induction of autoim-
munity by environmental stimuli (15).
In humans, long-term thymectomized MG patients dis-
play mild T-cell lymphopenia, which is associated with hyper-
gammaglobulinemia and evidence of B cell hyperreactivity. In
addition, many of these patients have high titers of a variety
of autoantibodies, including anti-dsDNA and anticardiolipin
antibodies (12). The high frequency (1.2-2.5%) of co-existence
of thymoma and SLE may reflect the loss of thymic function
in the presence of a tumor (16).
In this report, we described two cases of SLE in MG patients
following thymectomy. Based on both the animal and human
studies, thymectomy is expected to facilitate the development
of autoimmune disease in an age-dependent manner in the
setting of continuous environmental stimulation, particularly
in genetically predisposed individuals. This sequence of events
may be initiated by the loss of suppressor T cells and immune
surveillance after thymectomy in patients with MG. Thus, it
is unlikely that postthymectomy lupus occurs by coincidence
in MG patients.
In our two patients, thymectomy had been performed 3
months or 13 yr before the occurrence of SLE. In other stud-
ies, SLE developed at highly variable time intervals of between
3 months and 18 yr after thymectomy (8). Polyarthritis and
polyarthralgia are the most common manifestations of post-
thymectomy lupus (combined data from several case reports).
Other frequent manifestations include skin rashes, fever, cytope-
nia, and pleuritis. The rare SLE manifestations of optic neu-
ritis and transverse myelitis have been reported in two cases
(17, 18). In our patients, polyarthritis was the main manifes-
tation of SLE. Owing to the limited number of cases examined,
it is impossible to compare the clinical features with those of
other SLE patients.
In conclusion, although thymectomy is the effective treat-
ment modality in patients with MG, our findings and the
observations of others support the view that this surgical option
may be a precipitating factor for other autoimmune diseases,
such as SLE. Further investigations will reveal the effects of
thymectomy on the immune system in humans. Nonetheless,
the possibility that novel autoimmune diseases emerge fol-
lowing thymectomy cannot be ignored.
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